Singer AC, Kirchhelle C, Roberts AP. (Inter)nationalising the antibiotic research and development pipeline. Lancet Infect Dis 2019; published online Nov 18. https://doi.org/10.1016/S1473-3099(19)30552-3—In this Personal View, a reference to the Global Antibiotic Research and Development Partnership as a push incentive on the first page has been removed, and two personal communications from Kevin Outterson have been reworded. The third sentence of the second paragraph should read “Developers can then move promising compounds to the US Biomedical Advanced Research and Development Authority (BARDA) for evaluation of possible funding of phase 2 and 3 trials”, and the third sentence of the third paragraph should read “In the case of the EU European Gram-Negative Antibacterial Engine initiative, €100 million of public funds during 6 years was apparently unable to generate sufficient private involvement by industry partners, leading to the initiative being scheduled to end in 2020”. These corrections have been made to the online version as of Nov 28, 2019, and will be made to the printed version.

中文翻译：

---

更正《柳叶刀感染病》 2019; 于11月18日在线发布.https：//doi.org/10.1016/S1473-3099（19）30552-3。

歌手AC，Kirchhelle C，Roberts AP。（相互）国有化抗生素研发渠道。柳叶刀感染Dis 2019; 11月18日在线发布.https：//doi.org/10.1016/S1473-3099（19）30552-3—在此“个人观点”中，删除了第一页对全球抗生素研究与开发合作伙伴关系的推动动机，并改写了凯文·奥特森（Kevin Outterson）的两封个人通讯。第二段的第三句应为“开发人员然后可以将有前途的化合物移交给美国生物医学高级研究与开发管理局（BARDA），以评估2期和3期试验的可能资助”，第三段的第三句应为“阅读“就欧盟“欧洲革兰氏阴性细菌发动机计划”而言，六年内的1亿欧元公共资金显然无法引起行业合作伙伴的充分私人参与，导致该计划定于2020年结束。” 这些更正已于11月28日针对在线版本进行，